Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Human Genetics

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The glucagon-like peptide-1 receptor agonist, Ex4, reduces intromission in sexually experienced male mice.

Psychoneuroendocrinology·2026

Same author

Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat.

Acta neuropsychiatrica·2026

Same author

Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents.

Behavioural brain research·2026

Same author

Deciphering multiway multiscale brain network connectivity from birth to 6 months.

Communications biology·2026

Same author

(-)-OSU6162 reduces freezing elicited by context-conditioned fear in rats.

Journal of psychopharmacology (Oxford, England)·2025

Same author

Mental health in sexual minorities: Change over time in a Finnish population-based sample.

Psychological medicine·2025

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

The dopamine transporter gene (DAT1) polymorphism is associated with premature ejaculation.

Pekka Santtila¹, Patrick Jern, Lars Westberg

¹Center of Excellence in Behavior Genetics, Department of Psychology, Abo Akademi University, Turku, Finland.

The Journal of Sexual Medicine

|February 10, 2010

Summary

The dopamine transporter gene (DAT1) 10R10R genotype is linked to a lower threshold for ejaculation, suggesting dopamine

More Related Videos

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

Related Experiment Videos

Last Updated: Jun 16, 2026

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

Area of Science:

Neuroscience
Genetics
Human Sexuality

Background:

Brain dopamine (DA) neurotransmission is implicated in ejaculation control.
Premature ejaculation has a partially hereditary basis.
The dopamine transporter gene (DAT1) plays a role in regulating dopamine levels.

Purpose of the Study:

To investigate the association between the dopamine transporter gene (DAT1) polymorphism and premature ejaculation.
To determine if specific DAT1 genotypes influence ejaculatory control.

Main Methods:

A cohort of 1,290 men provided self-reports on ejaculatory function indicators (anteportal ejaculation, thrusts, latency, control) and saliva samples for DNA analysis.
Retrospective self-reports assessed four key indicators of ejaculatory function.
DNA analysis identified genotypes of the dopamine transporter gene (DAT1).

Main Results:

Men with the 10R10R DAT1 genotype showed a significantly lower threshold for ejaculation across multiple indicators compared to 9R9R/9R10R carriers.
This association remained significant after controlling for demographic and sexual behavior variables.
The findings suggest a specific dopaminergic influence on ejaculation, independent of other sexual behaviors.

Conclusions:

The study supports the role of dopaminergic neurotransmission in the control of ejaculation.
The DAT1 gene polymorphism is associated with variations in ejaculatory function.
Dopamine transporter genetics may contribute to the development of premature ejaculation.